Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis

The aim of this study was to evaluate the long-term response to rituximab in patients with chronic and refractory immune thrombocytopenic purpura (ITP). Adults with ITP fail to respond to conventional therapies in almost 30% of cases, developing a refractory disease. Rituximab has been successfully...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Chavez, Jaime, Majluf-Cruz, Abraham, Montiel-Cervantes, Laura, Esparza, Miriam García-Ruiz, Vela-Ojeda, Jorge
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040174/
https://www.ncbi.nlm.nih.gov/pubmed/17874322
http://dx.doi.org/10.1007/s00277-007-0317-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040174/
https://www.ncbi.nlm.nih.gov/pubmed/17874322
http://dx.doi.org/10.1007/s00277-007-0317-3

Ejemplares similares